US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: April 9, 2020
Clear
SKU: GMS-3201 Category:

The overall US therapeutic plasma exchange market is expected to reach USD 387.6 million by 2025, rising over the forecast period at a CAGR of 10.5%. Factors such as the growing prevalence of neurological diseases; rising the clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing multiple sclerosis prevalence in the US are driving the growth of the US market for therapeutic plasma exchanges.

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 1

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 2

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 3

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 4

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 5

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 6

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 7

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - 2020 to 2025 8

1 US Therapeutic Plasma Exchange Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 US Therapeutic Plasma Exchange Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 US Therapeutic Plasma Exchange Market – Market Forces
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Opportunities
4.2.3 Challenges
4.3 Porters Analysis of Market
4.3.1 Bargaining power of suppliers
4.3.2 Bargaining powers of customers
4.3.3 Threat of new entrants
4.3.4 Rivalry among existing players
4.3.5 Threat of substitutes

5 US Therapeutic Plasma Exchange Market – By Indication (Market Size – & million/billion)
5.1 Neurological Disorders
5.2 Hematology Disorders
5.3 Renal Disorders
5.4 Autoimmune Disorders
5.5 Metabolic Disorders

6 US Therapeutic Plasma Exchange Market – Entropy
6.1 New product launches
6.2 M&A’s, collaborations, JVs and partnerships

7 US Therapeutic Plasma Exchange Market Company Profile (Key Players)
7.1 Market Share, Company Revenue, Products, M&A, Developments
7.2 Company 1
7.3 Company 11 & more

8 US Therapeutic Plasma Exchange Market – Appendix
8.1 Sources
8.2 Abbreviations